1yr
Heart Failure Connect
1yr
Acute Heart Failure Is a Malignant Process: But We Can Induce Remission - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37889197/
Acute heart failure is a common and increasingly prevalent condition, affecting >10 million people annually. For those patients who survive to discharge, early readmissions and death rates are >30% everywhere...
Acute heart failure affects millions globally, with high readmission and death rates. Rapid, full-dose treatment can induce remissions, highlighting the urgent need for collaborative efforts to improve implementation and outcomes.
1yr
Multiprofessional heart failure self-development framework - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38242561/
People with heart failure can be complex and have needs that require input from a broad range of specialties. This publication focuses on the vital impact of wider multidisciplinary groups...
This framework outlines essential heart failure competencies for diverse healthcare professionals, emphasizing multidisciplinary collaboration to address complex patient needs, supporting future professionals in delivering comprehensive heart failure care.
1yr
Mitochondrial Structure and Function in Human Heart Failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38963864/
Despite clinical and scientific advancements, heart failure is the major cause of morbidity and mortality worldwide. Both mitochondrial dysfunction and inflammation contribute to the development and progression of heart failure....
This review explores mitochondrial dysfunction and inflammation in heart failure, focusing on mitochondrial dynamics, ultrastructure changes, and therapeutic targets to improve cardiac function and energy metabolism.
1yr
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38558314/
Empagliflozin exerts a consistent benefit on cardiovascular outcomes and renal function decline, irrespective of baseline insulin use, and reduces the need for sustained insulin initiation in patients with HF and...
Empagliflozin benefits cardiovascular outcomes and renal function in heart failure patients with diabetes, regardless of baseline insulin use, and reduces the need for sustained insulin initiation in non-insulin users.